T1 d exchange Overview

260 views

Published on

T1D Exchange is a not for profit organization whose mission is to accelerate therapies to the market to improve health outcomes on a path to a cure to type 1 diabetes. T1D Exchange possesses a clinic network of 69 clinics, a patient registry of 27,000 patients, a biorepository, and a patient engagement platform that builds an online community for people with type 1 diabetes.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
260
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
8
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

T1 d exchange Overview

  1. 1. 1T1D Exchange Overview, April 2013
  2. 2. T1D Exchange Vision2 The T1D Exchange model was conceptualized as a solution to mitigate barriers and inefficiencies for clinical and translational research.
  3. 3. Operationalizing T1D Exchange3 2009 2010 2011 2012 Design & Clinic RFP Registry Registry 2013 Grant Funded/ Enrollment Annual Renewal Request Launch Updates
  4. 4. Original Concept4 Registry Biorepository Exchange Patient Community
  5. 5. An Integrated Model For Research5 • 26,000+ patients • 69 clinics • 150 parameters • 100K+ Type 1s tracked • 100+ clinicians • Longitudinal study • Adults & Peds • Leading KOLs Clinic Clinic • Coordinated IRB • Annual updates • Ethnically diverse Network Registry • Specialty Modules • 1,000 C-peptide Glu Biobank study • 5,000+ Members • Real world data • 6,000 samples • HIPAA • Well characterized • On-line research • Protocol development
  6. 6. Improving Care and Accelerating Development 6 Patient Care & Understand state of T1D Clinical Research  Understand human disease care & management  Discovery of new Quality of life pathways & targets Health care costs  Access to patients Patient & caregiver needs for studies & trials Clinician needs  Leverage clinicians, network & patients Segment & stratify patients  Consumer & prescriber insight Research & Development
  7. 7. Patient Characterization7 Laboratory Tests Ocular Health Family History T1D & T2D Time of Diagnosis Blood Sugars Payer/Insurance Device Use Medication Usage Pregnancy Insulin Use Medical Procedures Patient Phenotype Co-Morbidity
  8. 8. T1D Exchange Personnel8  15 Staff  7 Staff  15 StaffClinic Network & Registry  Director  Director  Senior  Coordinators  Project Managers Management  Project Managers  Protocol Expertise  Strategic Alliance  Epidemiologists  Research Assistants  Operations T1D First & GLU  Statisticians  Coordinators  IT Team Biorepository  KOL’s  Biobank Staff  MarCom  IT Team  Content & Community
  9. 9. T1D Exchange Products & Services9 Solutions to Research Obstacles—Faster, Validated Results  MyGlu & Exploration Portal  Patient engagement platform  Access to T1DX data  Specialty services  Patient recruitment & study/trial support  Custom study modules  Dynamic biorepository  Living biobank strategy  Ability to collect targeted samples
  10. 10. Glu: Engagement Platform10 Patient & Caregiver Community: A Community with a purpose!  Community with a common goal: improve outcomes & lifestyle of T1D patients  Support patients on a daily basis through connecting, education and empowerment  Integrated with the most comprehensive national T1D patient registry  Real time access point for community driven research using an innovative mobile platform
  11. 11. Question Of The Day11
  12. 12. Question Of The Day12  “I change my infusion site every 2 days. Ive found that my blood sugars start to go up on the 3rd day if I leave it in any longer. So every other day no matter what. The reservoir I change when it is empty. I keep an eye on it to make sure I dont get caught away from home with no insulin.”  “Depends on if they both run out at the same time. Why waste a good 30 or 40 units of insulin just because the site has gone bad?”  “Three years ago I was diagnosed with DKA of unknown origin, and one possible reason was infection at the infusion site, which I had been using for about five days. When I see my endo he checks my sites and I have been told more than once that I need to change every three days. Finances are a problem, so that is why I try to use sets longer than thee days. I never thought about reusing the reservoirs, but I may try that now, even though reservoirs are significantly cheaper than infusion sets.”
  13. 13. Education & Study Recruitment13
  14. 14. Biorepository Key Features14 Going from Genotype to Phenotype, with Patient Specificity  Protocol driven procurement and analysis  Access patients under coordinated IRB for studies  Can recruit through registry and Glu  Collect biosamples longitudinally  Developed Virtual Biobank  Re-contact patients for additional studies  Access existing biosamples for studies  Integrated with the patient registry  Patient biologic data linked to clinical information  Over 6,000 existing biosamples Locating and procuring the right sample from the right patient at the right time.
  15. 15. Accelerating Timelines16 Patient Needs & Discovery Development and Delivery Monitor Post Targeted Evaluate Product Launch Marketing Studies & Test & Drug Monitoring Exchange Supporting the research continuum!
  16. 16. T1D Exchange In Action16 Ongoing Studies:  Observational Studies:  USC–RAND Study: Socioeconomic Determinants of Health Literacy, Diabetes  Sanofi TEENS Quality of Life Study Awareness and Treatment Adherence  Goal: 500 subjects  Goal: 2,000 patients from various sources  Completed within 4 months  T1DX registry recruited 1,663 patients within  25% enrollment each month 60 days (90% enrolled within 10 days)  0 screening failures  No patients discontinued  Interventional Studies:  Joint T1DX-HCT Study: Residual C-Peptide  Large Pharma Partner  Goal: 1,000 patients  Goal: 300 subjects  First 800 patients recruited within 3 months  Biotechnology  approaching completion of enrollment  Novel glucagon: studies, co-creation and first T1DX development partnership In Development:  Metformin Study: T1DX/HCT Partnership  LADA Study: Partnership with CHOP, Funded by NIDDK
  17. 17. Abstracts and Publications17 Publications The T1D Exchange clinic registry (Journal of Endocrinology & Metabolism, 12/2012) Evidence of a Strong Association Between Frequency of Self-Monitoring of Blood Glucose and Hemoglobin A1C Levels in T1D Exchange Clinic Registry Participants (Diabetes Care, 2/2013) A Comparison of Autoantibody Positive and Autoantibody Negative Pediatric Participants Enrolled in the T1D Exchange Clinic Registry (Journal of Diabetes, 2/2013) Most Youth With Type 1 Diabetes in the T1D Exchange Clinic Registry Do Not Meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines (Diabetes Care, 1/2013) Abstracts 32 Abstracts and posters presented at 11 meetings around the globe  ADA, EASD, ISPAD, ATTD and DT&T
  18. 18. Partnering With T1D Exchange18  We are a nonprofit with a different strategy  Develop tools, technologies and systems  Accelerate therapies to market  All surpluses reinvested into our research mission  There is a mission motive, not a profit motive  Incubated with private charity support by Helmsley Charitable Trust  Self-sustaining through Partnerships
  19. 19. 19 Thank You Questions/Discussion

×